KR102750630B1 - 하이드록시벤조산 유도체, 및 그 제조방법 및 용도 - Google Patents

하이드록시벤조산 유도체, 및 그 제조방법 및 용도 Download PDF

Info

Publication number
KR102750630B1
KR102750630B1 KR1020197016316A KR20197016316A KR102750630B1 KR 102750630 B1 KR102750630 B1 KR 102750630B1 KR 1020197016316 A KR1020197016316 A KR 1020197016316A KR 20197016316 A KR20197016316 A KR 20197016316A KR 102750630 B1 KR102750630 B1 KR 102750630B1
Authority
KR
South Korea
Prior art keywords
mitochondrial
delete delete
compound
chain
antioxben
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197016316A
Other languages
English (en)
Korean (ko)
Other versions
KR20190132622A (ko
Inventor
마리아 페르난다 마틴스 볼게스
폴로 조지 구베이아 시모에스 다 실바 올리베이라
조세 칼로스 산토스 테익세이라
페르난도 카기드 페이진
아나 카타리나 고메스 올리베이라
Original Assignee
유니베르시다데 도 포르토
센트로 데 뉴로씨엔씨아스 이 바이올로지아 셀룰라
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니베르시다데 도 포르토, 센트로 데 뉴로씨엔씨아스 이 바이올로지아 셀룰라 filed Critical 유니베르시다데 도 포르토
Publication of KR20190132622A publication Critical patent/KR20190132622A/ko
Application granted granted Critical
Publication of KR102750630B1 publication Critical patent/KR102750630B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020197016316A 2016-12-29 2017-12-29 하이드록시벤조산 유도체, 및 그 제조방법 및 용도 Active KR102750630B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT109818 2016-12-29
PT10981816 2016-12-29
PCT/IB2017/058508 WO2018122789A1 (en) 2016-12-29 2017-12-29 Hydroxybenzoic acid derivatives, methods and uses thereof

Publications (2)

Publication Number Publication Date
KR20190132622A KR20190132622A (ko) 2019-11-28
KR102750630B1 true KR102750630B1 (ko) 2025-01-06

Family

ID=61074472

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197016316A Active KR102750630B1 (ko) 2016-12-29 2017-12-29 하이드록시벤조산 유도체, 및 그 제조방법 및 용도

Country Status (8)

Country Link
US (1) US11078222B2 (cg-RX-API-DMAC10.html)
EP (1) EP3562830B1 (cg-RX-API-DMAC10.html)
JP (2) JP2020503280A (cg-RX-API-DMAC10.html)
KR (1) KR102750630B1 (cg-RX-API-DMAC10.html)
CN (1) CN110114365B (cg-RX-API-DMAC10.html)
BR (1) BR112019011303B1 (cg-RX-API-DMAC10.html)
CA (1) CA3048966A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018122789A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3925961A4 (en) * 2019-10-30 2022-05-11 Fusion Biotechnology Co., Ltd. Mitochondria-targeting compound and composition comprising same for treating or preventing aging-related diseases
WO2023053059A1 (en) * 2021-09-30 2023-04-06 Universidade Do Porto Antifouling compound, method and uses thereof
WO2023220365A1 (en) * 2022-05-13 2023-11-16 Virginia Tech Intellectual Properties, Inc. Mitochondrial antioxidant treatment for cask-linked neurodevelopmental disorders
US20260097092A1 (en) * 2022-09-21 2026-04-09 Ulsan National Institute Of Science And Technology Pharmaceutical composition containing mitochondria-targeting compound as active ingredient for treating macular degeneration
KR102894216B1 (ko) * 2022-12-15 2025-12-18 울산과학기술원 Trap-1 억제제
CN116210697B (zh) * 2023-03-02 2024-05-14 西北农林科技大学 反式肉桂酸在提高苹果树腐烂病抗性中的应用
KR20250126454A (ko) * 2024-02-16 2025-08-25 울산과학기술원 암 세포의 티오에스테라제 및 활성산소종에 의해 자가 조립 중합되는 단량체 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010126719A1 (en) * 2009-04-27 2010-11-04 Mcw Research Foundation, Inc. Neuroprotective compounds and their use
WO2015075200A1 (en) * 2013-11-22 2015-05-28 Medical Research Council Mitochondria-targeted dicarbonyl sequestering compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018010829A (es) * 2016-03-08 2019-02-07 Univ Michigan Regents Inductores de molécula pequeña de especies de oxígeno reactivo e inhibidores de la actividad mitocondrial.
US10913757B2 (en) * 2016-10-14 2021-02-09 Universidade Do Porto Hydroxycinnamic derivatives, methods and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010126719A1 (en) * 2009-04-27 2010-11-04 Mcw Research Foundation, Inc. Neuroprotective compounds and their use
WO2015075200A1 (en) * 2013-11-22 2015-05-28 Medical Research Council Mitochondria-targeted dicarbonyl sequestering compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PloS one, 10(8), e0136852.
Toxicology and applied pharmacology, 309, pp.2-14.

Also Published As

Publication number Publication date
US11078222B2 (en) 2021-08-03
KR20190132622A (ko) 2019-11-28
JP2020503280A (ja) 2020-01-30
BR112019011303B1 (pt) 2023-03-14
EP3562830A1 (en) 2019-11-06
WO2018122789A1 (en) 2018-07-05
JP2023051961A (ja) 2023-04-11
JP7689690B2 (ja) 2025-06-09
CN110114365B (zh) 2022-12-13
CA3048966A1 (en) 2018-07-05
BR112019011303A2 (pt) 2019-10-08
EP3562830B1 (en) 2023-06-07
US20190330249A1 (en) 2019-10-31
EP3562830C0 (en) 2023-06-07
CN110114365A (zh) 2019-08-09

Similar Documents

Publication Publication Date Title
JP7689690B2 (ja) ヒドロキシ安息香酸誘導体、その方法および使用
JP7111730B2 (ja) ヒドロキシケイ皮酸誘導体、その方法および使用
Teixeira et al. Development of a mitochondriotropic antioxidant based on caffeic acid: proof of concept on cellular and mitochondrial oxidative stress models
Estrada et al. New cinnamic–N-benzylpiperidine and cinnamic–N, N-dibenzyl (N-methyl) amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties
ES3033538T3 (en) Novel compounds for treating mitochondrial disease
Hawash et al. Novel indole-pyrazole hybrids as potential tubulin-targeting agents; Synthesis, antiproliferative evaluation, and molecular modeling studies
Bai et al. Targeting (cellular) lysosomal acid ceramidase by B13: Design, synthesis and evaluation of novel DMG-B13 ester prodrugs
Silvia et al. Novel molecular combination deriving from natural aminoacids and polyphenols: Design, synthesis and free-radical scavenging activities
An et al. Synthesis, in vitro and in vivo evaluation of new hybrids of millepachine and phenstatin as potent tubulin polymerization inhibitors
EP3129014B1 (fr) Nouveaux composes organo-selenies, procédé de fabrication et applications en pharmacie comme agents anti-tumoraux
US20210276979A1 (en) Therapeutic compounds
JP2019518029A (ja) グルタチオンを標的に送達するための化合物ならびにその製造方法および使用方法
Fu et al. Identification of nitric oxide-releasing derivatives of oleanolic acid as potential anti-colon cancer agents
CN109069448B (zh) 用于治疗肝癌的组合物和方法
JP7635923B2 (ja) 化合物およびその用途
EP3353186B1 (en) Highly efficient nrf2 activators-co-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation
WO2025165846A1 (en) Rhodoquinone mimetics and methods of making and using thereof
JP6173440B2 (ja) 新規美白剤
KR20150002022A (ko) 새로운 사이클로헥산디아민 유도체 및 이를 이용한 화장료 조성물
ITBO20070618A1 (it) Composti organici utili per il trattamento di malattie neurodegenerative, loro utilizzazioni e metodo per la loro preparazione

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190605

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201228

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230511

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240219

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20241007

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250102

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250102

End annual number: 3

Start annual number: 1

PG1601 Publication of registration